VIDEO: ‘The future looks bright’ for diabetic macular edema treatment

Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Diabetic macular edema is still a very challenging disease to treat because it’s chronic and patients often have recurrence of their edema. With the more recently approved 8 mg of aflibercept and 6 mg of faricimab, physicians have more treatment options for their patients while decreasing the treatment burden of frequent office visits. In the pipeline, investigators are also evaluating vector-based therapies that might deliver intravitreal therapies for patients with longer productions of antibodies inside the eye. In addition, we’re looking at different mechanisms for treatments, such as tyrosine kinase inhibitors, which may also provide longer durability of treatment. The future looks bright with all these novel medicines being developed for diabetic macular edema.